BR0012478B1 - Derivados de aminotiazóis, composições farmacêuticas compreendendo os mesmos, bem como seu uso e processo de preparação - Google Patents

Derivados de aminotiazóis, composições farmacêuticas compreendendo os mesmos, bem como seu uso e processo de preparação

Info

Publication number
BR0012478B1
BR0012478B1 BRPI0012478-8B1A BR0012478A BR0012478B1 BR 0012478 B1 BR0012478 B1 BR 0012478B1 BR 0012478 A BR0012478 A BR 0012478A BR 0012478 B1 BR0012478 B1 BR 0012478B1
Authority
BR
Brazil
Prior art keywords
well
pharmaceutical compositions
preparation process
aminothiazole derivatives
aminothiazole
Prior art date
Application number
BRPI0012478-8B1A
Other languages
English (en)
Other versions
BR0012478A (pt
Inventor
Evelyne Fontaine
Michel Geslin
Danielle Gully
Antoine Pradines
Pierre Roger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR0012478A publication Critical patent/BR0012478A/pt
Publication of BR0012478B1 publication Critical patent/BR0012478B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
BRPI0012478-8B1A 1999-07-15 2000-07-11 Derivados de aminotiazóis, composições farmacêuticas compreendendo os mesmos, bem como seu uso e processo de preparação BR0012478B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9909144A FR2796380B3 (fr) 1999-07-15 1999-07-15 Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
PCT/FR2000/001995 WO2001005776A1 (fr) 1999-07-15 2000-07-11 Derives d'aminothiazole et leur utilisation comme ligands des recepteurs crf

Publications (2)

Publication Number Publication Date
BR0012478A BR0012478A (pt) 2002-04-02
BR0012478B1 true BR0012478B1 (pt) 2013-10-15

Family

ID=9548107

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0012478-8B1A BR0012478B1 (pt) 1999-07-15 2000-07-11 Derivados de aminotiazóis, composições farmacêuticas compreendendo os mesmos, bem como seu uso e processo de preparação

Country Status (36)

Country Link
US (2) US6586456B1 (pt)
EP (1) EP1200419B1 (pt)
JP (1) JP4949582B2 (pt)
KR (1) KR100707320B1 (pt)
CN (1) CN1167692C (pt)
AR (1) AR024747A1 (pt)
AT (1) ATE264315T1 (pt)
AU (1) AU772683B2 (pt)
BR (1) BR0012478B1 (pt)
CA (1) CA2378792C (pt)
CO (1) CO5200792A1 (pt)
CZ (1) CZ300937B6 (pt)
DE (1) DE60009911T2 (pt)
DK (1) DK1200419T3 (pt)
EA (1) EA005159B1 (pt)
EE (1) EE05004B1 (pt)
ES (1) ES2220504T3 (pt)
FR (1) FR2796380B3 (pt)
HK (1) HK1045692B (pt)
HU (1) HU229069B1 (pt)
IL (2) IL147282A0 (pt)
IS (1) IS2314B (pt)
ME (1) MEP26608A (pt)
MX (1) MXPA02000545A (pt)
NO (1) NO324352B1 (pt)
NZ (1) NZ516397A (pt)
PL (1) PL206515B1 (pt)
PT (1) PT1200419E (pt)
RS (1) RS50443B (pt)
SI (1) SI1200419T1 (pt)
SK (1) SK287069B6 (pt)
TR (1) TR200200125T2 (pt)
TW (1) TWI278453B (pt)
UA (1) UA73125C2 (pt)
WO (1) WO2001005776A1 (pt)
ZA (1) ZA200200221B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2423156A1 (en) * 2000-09-21 2002-03-28 Bristol-Myers Squibb Company Substituted azole derivatives as inhibitors of corticotropin releasing factor
EP1423113A4 (en) * 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
US6993173B2 (en) 2001-10-12 2006-01-31 Duke University Methods for estimating probe cell locations in high-density synthetic DNA microarrays
AU2005250056A1 (en) 2004-06-03 2005-12-15 Athlomics Pty Ltd Agents and methods for diagnosing stress
US7410988B2 (en) * 2004-08-13 2008-08-12 Genentech, Inc. 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
EP1834641A1 (en) * 2006-03-16 2007-09-19 Sanofi-Aventis Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
HUP0900267A2 (en) 2009-04-30 2011-03-28 Sanofi Aventis Process for preparing of thiazole amines and intermediates thereof
EP2841068B8 (en) * 2012-04-23 2019-03-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Crhr1 antagonists for use in the treatment of patients having crh overactivity
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
NZ722122A (en) 2014-01-21 2020-06-26 Neurocrine Biosciences Inc Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
JP2022000473A (ja) * 2018-12-07 2022-01-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
TW202033193A (zh) 2018-12-07 2020-09-16 美商紐羅克里生物科學有限公司 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式
EP4034111A1 (en) * 2019-09-27 2022-08-03 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
JOP20220329A1 (ar) 2020-06-10 2023-01-30 مضاد مستقبل crf1 لعلاج فرط تنسج الكظر الخلقي

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
FR2714059B1 (fr) * 1993-12-21 1996-03-08 Sanofi Elf Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2754258B1 (fr) * 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
DE60009911T2 (de) 2005-03-10
EP1200419A1 (fr) 2002-05-02
PL352901A1 (en) 2003-09-22
YU1302A (sh) 2005-03-15
CA2378792C (en) 2009-11-10
MEP26608A (en) 2010-06-10
BR0012478A (pt) 2002-04-02
EE05004B1 (et) 2008-04-15
UA73125C2 (uk) 2005-06-15
EA005159B1 (ru) 2004-12-30
SK287069B6 (sk) 2009-11-05
JP4949582B2 (ja) 2012-06-13
CZ300937B6 (cs) 2009-09-16
IS2314B (is) 2007-11-15
FR2796380B3 (fr) 2001-08-17
EE200200022A (et) 2003-04-15
CZ2002137A3 (cs) 2002-04-17
AU772683B2 (en) 2004-05-06
US20070281919A1 (en) 2007-12-06
PL206515B1 (pl) 2010-08-31
EA200101234A1 (ru) 2002-08-29
KR100707320B1 (ko) 2007-04-13
SK382002A3 (en) 2002-07-02
MXPA02000545A (es) 2002-07-30
CN1370154A (zh) 2002-09-18
HUP0202387A3 (en) 2004-12-28
HU229069B1 (en) 2013-07-29
AR024747A1 (es) 2002-10-23
FR2796380A1 (fr) 2001-01-19
AU6452100A (en) 2001-02-05
ES2220504T3 (es) 2004-12-16
SI1200419T1 (en) 2004-08-31
WO2001005776A1 (fr) 2001-01-25
HK1045692B (zh) 2004-11-26
NO324352B1 (no) 2007-09-24
IL147282A0 (en) 2002-08-14
NO20020155D0 (no) 2002-01-11
US8420679B2 (en) 2013-04-16
TR200200125T2 (tr) 2002-09-23
ZA200200221B (en) 2003-04-30
NO20020155L (no) 2002-03-15
CA2378792A1 (en) 2001-01-25
US6586456B1 (en) 2003-07-01
DK1200419T3 (da) 2004-07-19
HUP0202387A2 (hu) 2002-11-28
IL147282A (en) 2008-04-13
JP2003505380A (ja) 2003-02-12
CN1167692C (zh) 2004-09-22
EP1200419B1 (fr) 2004-04-14
IS6219A (is) 2002-01-03
RS50443B (sr) 2010-03-02
CO5200792A1 (es) 2002-09-27
DE60009911D1 (de) 2004-05-19
TWI278453B (en) 2007-04-11
HK1045692A1 (en) 2002-12-06
KR20020015373A (ko) 2002-02-27
ATE264315T1 (de) 2004-04-15
PT1200419E (pt) 2004-07-30
NZ516397A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
BR0000908B1 (pt) derivados de 4-fenil-piridina, seu processo de preparação e seu uso, bem como medicamento que os contém
BRPI9907866B8 (pt) composição farmacêutica, bem como seu uso
BR0015254B1 (pt) compostos derivados de carbamoiloxialquil-azàlio, seu uso, bem como composiÇço farmacÊutica compreendendo os mesmos.
BR9706471B1 (pt) derivados de propiofenona, processo para prepração dos mesmos, composição farmacêutica compreendendo os mesmos, bem com seu uso.
EE05643B1 (et) Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
BR0012478B1 (pt) Derivados de aminotiazóis, composições farmacêuticas compreendendo os mesmos, bem como seu uso e processo de preparação
EE05292B1 (et) 6-alkenl-, 6-alknl- ja 6-epoksepotilooni derivaadid, nende valmistamismeetod ja kasutamine farmatseutilistes preparaatides
EE200200064A (et) Arüülmetüülkarbonüülaminotiasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena
BRPI0212137A2 (pt) diidropteridinonas, processos para prepará-las e seu uso como composições farmacêuticas
BR0017030B8 (pt) derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
ITMI991803A0 (it) Processo per la preparazione di formulazioni acquose per uso oftalmico
NO20032909D0 (no) Glukopyranosyloksypyrazolderivater samt medikamentell anvendelse derav
BR9816155B1 (pt) imidazotriazinonas 2-fenil-substituìdas como inibidores de fosfodiesterase, bem como medicamento e uso farmacêutico compreendendo as mesmas.
EE200200095A (et) Sulfonüülkarboksamiidi derivaadid, nende kasutamine, ravim ja nende valmistamismeetod
EE200300581A (et) Karboksamiid-asendatud fenüüluurea derivaadid ja nende kasutamine, ravim ja selle valmistamismeetod
BR9807848B1 (pt) Composto de arilsulfonamidas e análogos, bem como composição farmacêutica e uso dos mesmos.
NO20021689L (no) 5-leddede heterocykliske derivater, fremstilling derav og anvendelse som medikamenter
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
PT1216225E (pt) Novos derivados de acido aminodicarboxilico com propriedade farmaceuticas
EE04151B1 (et) Atsüülpiperasinüülpürimidiinide derivaadid, nendevalmistamine ja kasutamine ravimitena
EE200300327A (et) Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon
EE200100009A (et) Bensimidasoolid, nende valmistamine ja kasutamineravimitena
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
EE04497B1 (et) Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS (FR)

Free format text: ALTERADO DE: SANOFI-SYNTHELABO

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/10/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)